The FDA is looking into whether Daiichi Sankyo’s blood pressure medicine Benicar increases the risk of heart-related death. The regulatory body said it is evaluating data from a pair of clinical trials in which diabetes patients taking the drug, known chemically as olmesartan, had a higher rate of death from heart related causes compared with patients taking a placebo. In addition to reviewing data from the two studies, the FDA said it is considering additional ways to assess the cardiovascular effects of Benicar.